Lipoprotein Lp(a) levels are reduced by danazol, an anabolic steroid
article
OA: closed
CC0
⤵ 7 in-corpus citations
Limited metadata. Only one source feed has indexed
this record so far — no abstract, full text, or open-access copy is
available through Endo Lab. The
publisher's page (linked below)
is the canonical location for the actual content. If you have institutional
access, use "Find at my library".
AI-generated summary
Danazol, an anabolic steroid, was found to reduce lipoprotein Lp(a) levels.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (35)
- A Comparison of Plasma Protein Changes Induced by Danazol, Pregnancy, and Estrogens* via openalex
- Auswirkungen der Danazol-Therapie bei Endometriose auf Blutbild und Gerinnung via openalex
- Metabolic effects of danazol. via openalex
- Profound alterations of the lipoprotein metabolism during danazol treatment in premenopausal women via openalex
- THE EFFECT OF DANAZOL ON MENORRHAGIA, COAGULATION MECHANISMS, HAEMATOLOGICAL INDICES AND BODY WEIGHT via openalex
- Treatment with danazol and plasma glucagon concentration. via openalex
- doi:10.1038/330132a0 via openalex
- doi:10.1126/science.2530631 via openalex
- doi:10.1093/clinchem/18.6.499 via openalex
- doi:10.1016/s0950-351x(05)80082-5 via openalex
- W2997279704 via openalex
- W4285719527 via openalex
- W6663759778 via openalex
- W6793613985 via openalex
- doi:10.1016/0140-6736(91)92824-l via openalex
- doi:10.1016/0005-2760(84)90078-x via openalex
- doi:10.1001/jama.1990.03440010033016 via openalex
- doi:10.1016/0026-0495(86)90150-2 via openalex
- doi:10.1111/j.1365-2796.1989.tb01393.x via openalex
- doi:10.1016/0021-9150(90)90203-u via openalex
- doi:10.1038/339301a0 via openalex
- doi:10.2337/diacare.14.4.302 via openalex
- doi:10.1016/0021-9150(90)90177-k via openalex
- doi:10.1001/jama.263.1.35b via openalex
- doi:10.1016/0005-2760(79)90131-0 via openalex
- doi:10.1016/0021-9150(85)90041-3 via openalex
- doi:10.1056/nejm199011153232003 via openalex
- doi:10.1016/0140-6736(91)92161-t via openalex
- doi:10.1016/0002-8703(87)90552-7 via openalex
- doi:10.1016/0021-9150(91)90025-x via openalex
- doi:10.1161/01.atv.10.2.240 via openalex
- doi:10.1007/bf00288277 via openalex
- doi:10.1136/jcp.41.4.471 via openalex
- doi:10.1111/j.1699-0463.1963.tb01808.x via openalex
- doi:10.1016/s0022-2275(20)41577-9 via openalex
Cited by (7)
- Danazol causes significant changes in the cardiometabolic profile of patients with acquired aplastic anaemia 2025
- Livedoid vasculopathy and high levels of lipoprotein (a): response to danazol 2015
- Danazol – możliwości wykorzystania w leczeniu chorób hematologicznych 2014
- Lipodermatosclerosis: Successful Treatment with Danazol 2005
- Elevated serum lipoprotein(a) levels in young women with endometriosis 1997
- Danazol and plasma lipoprotein metabolism 1995
- Hormonal agents used in lowering lipoprotein(a) 1994
Source provenance
- europepmc
- last seen: 2026-06-11T06:19:48.454388+00:00
- openalex
- last seen: 2026-05-11T06:17:40.080092+00:00
- pubmed
- last seen: 2026-05-13T22:11:54.876058+00:00
License: CC0
· commercial use OK